Pharmacokinetics, Safety, and Efficacy of Brigatinib Monotherapy in Pediatric and Young Adult Participants With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid Tumors

PHASE1/PHASE2WithdrawnINTERVENTIONAL

Timeline

Start Date

September 1, 2020

Primary Completion Date

September 1, 2023

Study Completion Date

September 1, 2025

Conditions

Anaplastic Lymphoma Kinase Positive (ALK +) Anaplastic Large Cell LymphomaInflammatory Myofibroblastic TumorsSolid Tumors

Interventions

DRUG

Brigatinib

Brigatinib tablets

DRUG

Brigatinib AAF

Brigatinib age-appropriate formulation (AAF)